Clene to Present at the Emerging Growth Conference
Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, has announced its upcoming presentation at the Emerging Growth Conference on April 17, 2025, at 12:00 p.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, has announced its upcoming presentation at the Emerging Growth Conference on April 17, 2025, at 12:00 p.m. EDT. The virtual presentation will include a corporate update followed by a Q&A session.
The company specializes in developing therapies for conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Their flagship investigational treatment, CNM-Au8®, is a first-in-class therapy targeting mitochondrial function and the NAD pathway while reducing oxidative stress. The presentation will be accessible through the company's website and the conference portal, with replays available afterward through the Emerging Growth Conference YouTube Channel.
Details
News Market Reaction – CLNN
The recorded move for CLNN in the trading session of this news was +1.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Virtual Presentation Details
Date: April 17, 2025
Time of Presentation: 12:00 p.m. EDT
Format: Corporate update with Q&A
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast, along with accompanying slides, here: https://goto.webcasts.com/starthere.jsp?ei=1705403&tp_key=612b99c876&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth Conference YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.
About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com (617) 283-2856 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.